Cecilia Goldenberg


10+ years of biopharmaceutical and cell and gene experience, working in business development at PCT, Charles River and Lonza.

About Cecilia

Cecilia Goldenberg brings with her 10+ years of biopharmaceutical and cell and gene experience, during which she held business development positions at PCT, Charles River and Lonza. During that time, she also earned valuable CGT experience in development, manufacturing, and commercialization.

In 2014, she joined PCT, where she focused on the development of the proposal department and focused on driving growth of the clinical and commercial opportunities.

2019, Cecilia joined Lonza’s cell and gene business unit and lead the US with building out a robust pipeline of opportunities for modalities (including technology focus) included in autologous and allogeneic therapies: CD34 cells, CAR-T, MSC, induced pluripotent stem cells (iPSCs) as well as gene therapies such as adeno-associated virus (AAV), and lentiviral vector (LVV).


Director, Business Development

Charles River Labs
Director, Business Development

Hitachi Chemical Advanced Therapeutics Solutions (HCATS)
Associate Director, Business Development


California State University, Long Beach                                                                                                                                                                                             Bachelor of Arts: Journalism with an emphasis in Public Relations, Spanish

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.